Posted inPharmaceutical
New drug approvals by FDA in 2025
Our update for new drug approvals by the US Food and Drug Administration (FDA) in the first half (H1) of 2025 had pointed out how upheavals at the agency had…
Posted inCannabis
PORTUGAL CANNABIS COMPANIES LICENSED BY INFARMED (EU AUTHORITY) – 2026 MAR 28
The evolution of INFARMED-licensed companies in Portugal tells a story of strategic regulatory execution. In less than a decade, the country has built a pharmaceutical cannabis sector from zero to…
Posted inBiologic Drugs BioTech Medicines
The Biologics Build-Out: Tracking the 20 Biggest US Manufacturing Facility Investments
If you work in pharmaceutical manufacturing, you have likely noticed a fundamental shift in the air. Following a wave of announcements in 2025 and early 2026, the United States is…
Posted inBiologic Drugs BioTech Medicines
UCB banks on Georgia for $2bn biologics manufacturing facility
This new facility, which will reside in the same state as UCB’s US HQ in Smyrna, will produce biologics from the company’s portfolio and pipeline. UCB has chosen Georgia as…
Posted inAI Biologic Drugs BioTech Medicines
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
The partnership is the latest in a long line of AI-centric projects in drug discovery and development. Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery…
Posted inCannabis
Companies plan to cultivate 13.7 tons of cannabis in Germany in 2026
In Germany, companies plan to cultivate 13.7 tons of cannabis for medical or scientific purposes this year. The Federal Institute for Drugs and Medical Devices (BfArM) reported this amount to…
Posted inBiologic Drugs BioTech Medicines
Biopharma’s 2025 M&A boom
Even with Johnson & Johnson’s (J&J) $14.6bn buyout of Intra-Cellular Therapies in January setting a strong deal-making tone, 2025 still delivered a few surprises. A bidding war between Pfizer and…
The European Union‘s dependence on imports of API from third countries – challenges and EU initiatives
The European Union’s dependence on imports of active pharmaceutical ingredients (API) from third countries has emerged as a critical challenge to the resilience of pharmaceutical supply chains and public health.…
API Manufacturing: A New Medicine Security Proposal for Europe
Medicines for Europe, which represents generic drug manufacturers in Europe, has proposed a new medicine security contract for Europe as a means to address potential drug shortages in 2023,…
US dangerously dependent on China for APIs, KSMs
March 19, 2026 Chinese production of active pharmaceutical ingredients and key starting materials is putting Americans at risk, according to a bipartisan congressional committee. The United States must adopt an…